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Predegenerated Schwann cells–a 
novel prospect for cell therapy 
for glaucoma: neuroprotection, 
neuroregeneration and 
neuroplasticity
Adrian Smedowski 1,2,3, Xiaonan Liu 4, Marita Pietrucha-Dutczak 1, Iwona Matuszek 1, 
Markku Varjosalo 4 & Joanna Lewin-Kowalik 1
Glaucoma is an optic neuropathy that leads to irreversible blindness. Because the current therapies 
are not sufficient to protect against glaucoma-induced visual impairment, new treatment approaches 
are necessary to prevent disease progression. Cell transplantation techniques are currently considered 
to be among the most promising opportunities for nervous system damage treatment. The beneficial 
effects of undifferentiated cells have been investigated in experimental models of glaucoma, however 
experiments were accompanied by various barriers, which would make putative treatment difficult or 
even impossible to apply in a clinical setting. The novel therapy proposed in our study creates conditions 
to eliminate some of the identified barriers described for precursor cells transplantation and allows us 
to observe direct neuroprotective and pro-regenerative effects in ongoing optic neuropathy without 
additional modifications to the transplanted cells. We demonstrated that the proposed novel Schwann 
cell therapy might be promising, effective and easy to apply, and is safer than the alternative cell 
therapies for the treatment of glaucoma.
Glaucoma is an optic neuropathy that leads to the continuous and progressive destruction of retinal ganglion 
cells (RGC), whose axons form the optic nerve, and finally, to blindness1–3. The association between glaucoma 
development and increased intraocular pressure (IOP), the basic measurable pathogenic factor, varies worldwide 
and occurs clinically with higher frequency in Western countries than in Asian populations, however this is not 
the only identified risk factor of the neuropathy4–8. Since current therapeutic strategies, i.e. pharmacological and 
surgical approaches targeting increased IOP, are not sufficient enough to protect against glaucoma blindness, and 
to restore the function of already injured RGC, new effective therapeutic strategies focused on RGC neuroprotec-
tion and their regeneration are expected to be developed9.
Cell transplantation techniques, applying various types of stem and progenitor cells, are currently considered 
to be a very promising tool in advanced therapies for central nervous system (CNS) damage, including damage to 
the retina and optic nerve; however, many obstacles for their usage in the retina have already been described10–16. 
Concerning cell transplantation to the inner retina, there are two directions these therapies might take: RGC 
neuroprotection and RGC replacement17. In most studies of glaucoma cell therapies, only stem and progenitor 
cells are considered, and no prospects for mature, differentiated cell usage are discussed in recent reviews16–18.
Schwann cells (SC) are the major glial cells in the peripheral nervous system. They are capable of stimulating 
the regeneration of both the peripheral and central nervous systems19. SC-induced regeneration manifests in 
the generation of new axons as well as the branching of already existing ones20. There are several possibilities to 
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activate SC under various conditions such as in vivo predegeneration, which can last various amounts of time, 
or glucose-dependent in vitro activation; however, in situ 7-day nerve predegeneration, which occurs in vivo as 
a result of peripheral nerve injury, has been claimed to be the most effective21–24. After nerve injury, SC create 
an environment favorable to the spontaneous regeneration of axons due to secretion of adhesion molecules and 
various trophic factors; SC obtained from the injured nerve in this time-window (i.e., after 7 days) are highly 
active and viable25–27.
In the present study, based on experience and promising results of SC transplantations in different CNS inju-
ries, we introduced, for the first time, the allotransplantation of adult, differentiated SCs in a chronic, glaucoma-
tous optic nerve neuropathy. In the reference group, we generated an acute optic nerve neuropathy (i.e., optic 
nerve crush, ONC); additionally, we cultured ex vivo retinal explants. Our aim was to detect potential neuropro-
tective and pro-regenerative effects of applied SC therapy toward RGC under experimental conditions in chronic 
and acute optic neuropathy. We also considered the safety of the applied therapy and its potential future utility in 
clinical applications.
Results
SC’s secretome and SC’s homogenate does not contain neurotrophic factors. To evaluate 
purity of SC culture, we calculated the ratio of cells that were co-localized for the S100 protein and glial fibrillary 
acidic protein (GFAP) in relation to those that were DAPI counterstained for cell nuclei, this ratio was about 
99–100% (Fig. 1A–H). To confirm proteomic features of cultivated SC, culture medium samples and SC homoge-
nate were analyzed by mass spectrometry (MS). The most strongly represented components of SC proteome 
consisted of extracellular matrix components, adhesion molecules, growth factor binding proteins, ion channel 
modulators and proteins involved in antioxidant cell protection, neuronal cells growth and axonal development 
(see Supplementary Table 1). Other growth-related factors such as nerve growth factor (NGF), brain derived 
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF) and neurotrophin 3 (NT3), which are widely 
Figure 1. Schwann cells in in vitro, ex vivo and in vivo conditions. (A–H) – immunofluorescent characterization 
(A–D), SC in culture (E–G) and GFP expression after Lv-eGFP transduction (H). Scale bar = 50 μm (A–D,H); 500 
μm (E); 100 μm (F); 20 μm (G). (I–J) – ex vivo retinal explants. (I) – SC cultured with explants with intact ILM 
are covering retinal surfaces with no signs of intraretinal penetration. (J) – mechanical interruption of the ILM 
resulted in massive infiltration of retinal tissue by SC accompanied by damage of lamellar retinal architecture. 
Scale bar = 100 μm (I,J).  (K–N) – localization of SC after intravitreal transplantation in vivo. SC (arrows) 
detected as a bolus in vitreal space (K) on posterior lens surface (L) some of SC were integrated with retinal surface 
(M). Only single SC were observed in deeper retinal layers (N, arrow). Scale bar = 500 μm (K); 50 μm (L–N). GCL- 
ganglion cell layer; INL – inner nuclear layer; ONL – outer nuclear layer.
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described as characteristic of SC, were not detected. Positive controls demonstrated the ability to detect low con-
centrations of BDNF and CNTF in culture medium using MS.
Intraretinal migration of transplanted SC is associated with disruption of retinal architecture. 
We tested migration capacity of transplanted SC in ex vivo and in vivo conditions. In ex vivo retinal insert explants, 
localization of transplanted SCs depended on the inner limiting membrane (ILM) continuity. In explants with 
intact ILM, SC were located on explant surface, and only single cells were able to penetrate inside the retinal 
tissue (Fig. 1I). In explants with an interrupted ILM, massive infiltration of retinal tissue by SC was observed. 
This migration was associated with destruction of the lamellar structure of retina (Fig. 1J). In vivo transplanted 
SC were located mostly in the vitreous body, on the posterior lens capsule and on the retinal surface (Fig. 1K–M). 
In in vivo samples, only single cells were detected within deeper retinal layers (Fig. 1N, arrow). Transplanted SC 
demonstrated preserved typical cell morphology in in vivo conditions (Fig. 1M).
Transplanted SC prolong RGC survival in ex vivo retinal explants. In retinal insert explants 
co-cultured with SC and with intact ILM, the density of β 3tubulin-positive cells in the ganglion cell layer 
(GCL) after 10 days was significantly higher (2054 ± 461 cells) than in PBS-treated explants (1163 ± 295 cells) 
(Mann-Whitney U-test, p < 0.01) (Fig. 2A,C–H). SC cytoplasm on explant surfaces developed granular structure, 
a possible sign of secretory activity (Fig. 2B, arrow). In explants with interrupted ILM, identification of GCL was 
impossible due to the loss of the lamellar retinal structure (Fig. 1J). The presence of SC on the explant surface 
visibly reduced the number of apoptotic cells within inner retinal layers (Fig. 2I,J).
Evaluation of IOP in experimental glaucoma model. The mean 6-week IOP in ocular hyper-
tensive eyes was significantly higher than in healthy contralateral eyes (mean ± SD, 31.02 ± 5.5 mmHg and 
10.32 ± 0.54 mmHg, respectively, Wilcoxon paired test, p < 0.05). There was no difference between the mean IOP 
or the IOPs from each time-point when comparing ocular hypertensive eyes treated with SC and those treated 
with intravitreal PBS injection (Mann-Whitney U-test, p > 0.1) (Fig. 3A).
Optic nerve disc cupping in eyes with acute and chronic optic neuropathy. In fundus pictures, 
as shown before, we reported an increased cup/disc (c/d) ratio in glaucomatous eyes due to a thinning of the 
neuroretinal rim and a decreased c/d ratio in ONC eyes due to retinal nerve fiber edema (Fig. 3B–F). In the 
ONC control group (with intravitreal PBS injection), insight into eye fundus was very limited due to presence of 
exudation and capture of OCT scans was impossible. In OCT scans, retinal thinning in the glaucoma group (i.e., 
due to atrophy) and thickening in the optic nerve crush group (i.e., due to edema) were observed (Fig. 3G). A 
statistical comparison between SC treated and untreated animals was unable to perform due to the small sample 
size; however, for the glaucomatous eyes treated with SC optic nerve disc cupping, which is considered to be the 
most frequently used, tended to be slightly lower than in PBS injected eyes (Fig. 3D).
RGC bodies and optic nerve axons survival in experimental glaucoma and ONC is improved 
after SC transplantation. We hypothesized that intravitreal transplantation of predegenerated SC prevents 
RGC death in optic neuropathies. In the experimental glaucoma group, there were significant differences in the 
total number of cell bodies in GCL and their density between SC-treated and PBS-treated eyes (Mann-Whitney 
U-test, p < 0.01), as well as healthy control and PBS treated eyes (Wilcoxon paired test, p < 0.03); surprisingly, 
there was no significant difference between healthy control and SC-treated eyes (Wilcoxon paired test, p > 0.1) 
(Fig. 4 top row graphs, A–I). In the ONC group, significant differences in the total number of GCL cell bodies and 
density were observed between all groups: SC-treated vs PBS-treated eyes (Mann-Whitney U-test, p < 0.01) and 
healthy control eyes vs SC-treated and vs PBS-treated eyes (Wilcoxon paired test, p < 0.03 and p < 0.03, respec-
tively) (Fig. 4 top row graphs, M–U). Regarding optic nerve axons, there were differences in the total number and 
density of axons, similar to the differences noted in GCL cell bodies (SC-treated vs PBS-treated, healthy control 
eyes vs PBS-treated, and healthy control vs SC-treated (Mann-Whitney U-test, p < 0.01; p < 0.03 and p > 0.1, 
respectively, in the glaucoma group; and Mann-Whitney U-test, p < 0.01; p < 0.01 and p < 0.01, respectively, in 
the ONC group) (Fig. 4 top row graphs, J–L, V–X).
Based on retinal histology, to detect inflammatory responses in retina after SC transplantation (concerning 
safety of SC usage), we performed immunostainings against Iba-1 for microglial cells (including macrophages) 
and GFAP for glial cells. In these stainings, we did not observe any signs of exacerbation of glial or microglial 
cell infiltration in groups treated with SC (Supplementary Fig. 1A–J). In optic nerve longitudinal sections, SC 
treatment prevented the loss of the linear nerve architecture that was associated with a visibly delayed thinning of 
nerve fibers and reduced proliferation of glial cells (Supplementary Fig. 1K–T).
SC therapy induces neuroregeneration and RGC neurite outgrowth in ex vivo and in vivo con-
ditions. Since we showed that transplantation of SC might act neuroprotective towards RGC, the next ana-
lyzes focused on neurite outgrowth detection. In reversed P2 retinal explants, there were significant differences 
among all groups (i.e., control, BDNF- and SC-treated) with respect to the mean and total length and surface 
area of neurites, as well as the number and arboration of neurites (Mann-Whitney U-test, p < 0.01) (Fig. 5A–G). 
Neurite outgrowths exhibited a positive tropism that depended on SC localization (Fig. 5H). On Fig. 5I, real 
area of retinal explant, labeled with DAPI, is marked. Red arrows indicate intense neurite outgrowth in explant’s 
areas surrounded by SC, while areas with SC absent (marked with yellow arrow) showed visibly poorer out-
growth (Fig. 5I). SC-induced neurite outgrowths (i.e., positive for anti-GAP-43) were also observed in insert 
retinal explants (Fig. 5J–L). In in vivo experiments of both glaucoma and ONC treated with SC, GAP-43 positive 
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parallel nerve fiber growth was detected within retrobulbar, unmyelinated parts of optic nerves; this outgrowth 
was absent in PBS-treated eyes (Fig. 6A–F).
Figure 2. Ex vivo insert retinal explants characterization. (A) – density of cells in the GCL of explants 
cultured with SC suspension and PBS; SC treatment resulted with higher density of total cells in GCL as well 
as β 3tubulin positive RGC. (B) – SC on retinal explant surface with visible granular intracellular structure 
(arrow). (C–H) – β 3tubulin-positive cells in the GCL of explants treated with SC or PBS (C–F) – whole 
mounted explants; (G,H) – retinal cross-sections). (I,J) – TUNEL staining of explants cross cryosections 
revealed a decreased number of apoptotic cells in the SC surroundings (J). Scale bar = 50 μm (B–D,G–J); 
scale bar = 500 μm (E,F). GCL- ganglion cell layer; INL – inner nuclear layer; ONL – outer nuclear layer, SC – 
Schwann cells.
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SC-induced synaptic plasticity in experimental glaucoma. To detect if SC-induced neurites out-
growth is associated with increase of synaptic proteins expression, in vivo glaucoma samples were evaluated for 
expression of synaptic marker — synaptophysin — using immunofluorescence staining (Fig. 6G–I). In glauco-
matous retinas treated with PBS-injection, decreased expression of synaptophysin within the inner plexiform 
layer (IPL) and outer plexiform layer (OPL) was observed (Fig. 6I). SC treatment increased expression of syn-
aptophysin, particularly in IPL (i.e., in afferent synapses between RGC and bipolar cells). Additionally, synaptic 
marker expression in the GCL (that was absent even in healthy retinas) was visible (Fig. 6H). In SC-treated 
glaucoma samples, presence of increased retinal expression of synaptophysin, especially this visible in initial part 
of ganglion cells axons (RNFL) (Fig. 7C,D, small arrows; big arrows on panel D indicate RGC bodies), might 
be linked with accelerated axonal transport of this synaptic protein to newly grown projections that in theory 
should tend to create synaptic connections with their proper target. In healthy conditions, where neurites out-
growth within optic nerve was only accidentally seen, synaptophysin expression in GCL was visible only as single 
punctate staining (Fig. 7A, arrow). In PBS-treated glaucoma samples, where we did not see any signs of neurites 
outgrowth, also synaptophysin expression within GCL was absent (Fig. 7B).
Discussion
Directions in the development of cell therapies for glaucoma. Cell transplantation techniques are 
currently considered to be one of the most promising treatment options for CNS damage. The most studied 
direction of cell-based therapies in experimental ophthalmology is the transplantation of cells that, after adap-
tation to the environment of the eyeball, are designed to release factors affecting retinal neurons’ survival18. The 
other branch of ocular cell therapies, neuronal replacement, remains almost unachievable, mostly due to poor 
integration of grafted cells28–32. In recent years, idea of cell transplantation has been successfully introduced into 
experimental models of ocular hypertension, to study neuroprotection of RGC10–12,15. However, these studies are 
employing glaucoma models based on ocular hypertension, it would be also important to investigate neuropro-
tective effects of cell therapies in models mimicking normal-tension glaucoma33.
Figure 3. Mean IOP values in experimental glaucoma groups (A); stable elevated IOP with no differences 
between treated and control groups ensures “pressure independent” protective effects towards RGC.  
Examples of eye fundus evaluation (B-G). B – a schematic anatomical characterization of optic nerve disc in 
fundus photograph; 1-optic nerve disc diameter (red); 2-neuroretinal ring diameter (yellow); 3-optic nerve cup 
diameter (green); cup/disc (c/d) ratio=3/1; for healthy eyes c/d ratio~0.3. C-F – example fundus photographs 
and c/d ratio in healthy, glaucomatous and ONC eyes; small OCT scans represent examples of retinal thickness 
in parapapillary area. Increased c/d ratio in glaucomatous eyes due to a thinning of the neuroretinal rim and 
a decreased c/d ratio in ONC eyes due to retinal nerve fiber edema. G - OCT retinal parameters in healthy, 
glaucomatous and ONC eyes. In the ONC group with intravitreal PBS injection, insight into eye fundus was 
very limited and capture of OCT scans was impossible. A statistical comparison between groups of animals was 
not perform due to the small sample size. ONC - optic nerve crush; SC - Schwann cells.
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Placement of SC therapies for optic neuropathies. Based on a comparison of various cell populations, 
predominantly precursor cells, regarding the possibility of adapting them for use in spinal cord, hippocampus, 
retina and optic nerve diseases, SC appear to be particularly useful34,35. The idea of predegenerated SC therapy for 
glaucoma was based on available knowledge on CNS and PNS regeneration studies using peripheral nerve prede-
generation products, as well as SC in various animal models36–43. Thus far, SC activity was tested only in models of 
acute neuropathy — mostly optic nerve transection, in which transplanted SC or nerve predegeneration products 
improved the survival of RGC as well as promoted neurite outgrowths39,44,45.
Suspected mechanism of SC activity do not include neurotrophic factors. Although the observed 
effect of SC grafting and the safety and appropriateness of its use seems to not raise doubts, it is challenging to 
explain the exact mechanisms of SC activity in our study. The positive neuroprotective and pro-regenerative 
effect of activated SC therapy theoretically steps from three main groups of factors secreted by these cells, similar 
as described for mesenchymal stem cells, oligodendrocyte progenitor cells, Müller precursors and olfactory glial 
cells10–12,15. Among the factors that are identified as potentially important in regeneration, neurotrophic factors 
and their receptors (i.e., NGF, BDNF, CNTF, NT3), extracellular matrix components and both adhesion and 
membrane proteins have been described25–27,46. An additional, potentially important mechanism is increased 
Figure 4. Total number and density of DAPI- and NeuN-positive cells in the GCL and optic nerve axons in 
glaucoma and ONC eyes. The upper panel contains graphs presenting exact quantitative analysis and statistical 
comparisons. SC therapy showed neuroprotective activity towards RGC when compared with control PBS 
injection. A single asterisk indicates statistical significance at the level of p < 0.05, double asterisk p < 0.01 and 
triple asterisk p < 0.001. (A–I, M–U) – immunostainings of whole mounted retinas showing GCL cells positive 
for NeuN with visible reduced cells density within PBS-treated retinas (A–F in glaucoma group; M–R in ONC 
group) and β 3tubulin with marked lower density and thinning of RGC axons (G–I in glaucoma group and 
S–U in ONC group). (J–L), (V–X) – optic nerve cross-sections in glaucoma and ONC; optic nerves from PBS-
treated groups showed severe changes including gliosis, axons swelling and macrophages infiltration, while 
SC-treated groups presented only mild changes in glaucomatous optic nerves and moderate injury after ONC. 
Scale bar = 50 μm (D–F), (P–R); 500 μm (A–C), (M–O), (G–I), (S–U); 10 μm (J–L), (V–X) SC – Schwann cells; 
ONC – optic nerve crush.
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Figure 5. Neurite outgrowths in ex vivo retinal explants. (A–F) – color and reconstruction pictures of 
β 3tubulin-positive neurites, the most intense outgrowth was observed in SC-treated group, scale bar = 500 μm. 
(G) – quantitative stereological analysis of neurite outgrowths, SC significantly increased number, length and 
surface of growing neurites. (H) – positive tropism of neurite outgrowths in retinal explants culture in the 
direction of SC. (I) – real area of retinal explant labeled with DAPI (to improve interpretation), red arrows 
indicate intense neurite outgrowth in explant’s areas surrounded by SC, while areas with SC absence (marked 
with yellow arrow) showed visibly poorer outgrowth, scale bar = 500 μm. (J–L) – GAP43 immunostaining in 
insert retinal explants (cross-cryosections); in explants treated with PBS (J) decreased expression of GAP43 is 
visible. Under SC treatment, there is visible overexpression of a regeneration marker (K). L – growing axons 
within GCL. Scale bar = 50 μm (J,K); 20 μm (L). GCL- ganglion cell layer; INL – inner nuclear layer; ONL – 
outer nuclear layer. SC – Schwann cells; BDNF – Brain Derived Neurotrophic Factor.
www.nature.com/scientificreports/
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sensitivity of receptors to growth factors, which appears to be a result of barotrauma in the retina and optic nerve 
head47. In theory factors secreted by SC likely have synergistic effects as evidenced by the observation that admin-
istration of neurotrophic factors by themselves did not have as many beneficial effects as cell therapy47,48. In the 
current literature, contact between the membrane of SC and axons is described as an important factor that may be 
involved in axonal regrowth, however in our case, with limited intraretinal cell migration, this condition seems 
not to be so significant49. To describe characteristics of cultivated SC and identify potential mechanisms of inter-
actions with the retina, we performed proteomic analysis of the culture medium and SC homogenate. It is known 
that SC are a rich source of many biological agents that might be released into the extracellular space, affecting 
neighboring cells, other membrane-associated proteins are primarily responsible for the autocrine or paracrine 
regulation of SC themselves50,51. Proteomics of cell-free culture medium and of SC homogenate confirmed most 
of their known proteomic features and revealed the presence of extracellular matrix proteins, adhesion molecules, 
proteins associated with growth factors (i.e., their receptors and binding proteins), membrane proteins and mito-
chondrial enzymes; however, the expected presence of the neurotrophic factors (i.e., NGF, BDNF, CNTF, NT3) 
has not been confirmed, which was highly suprising. Additionally, MS analysis revealed the presence of a large 
group of proteins involved in cells’ oxidative stress defense and LRP2 receptor agonists (involved in neuronal 
development and axonal growth), which we suspect to be key mechanisms of SC activity in the present study. 
Evidences for the secretion of neurotrophic factors by SC are inconsistent in the literature. However, in some 
publications, the presence of neurotrophic factors has been identified in peripheral nerve homogenates, there are 
Figure 6. Neuroregeneration and neuroplasticity in vivo. (A–F) – longitudinal sections of retrobulbar, 
unmyelinated optic nerve portion. (A) – single GAP43-positive fibers in healthy optic nerve (arrows); (B) 
– ONC treated with PBS injection, no visible neurites outgrowth; (C) – ONC treated with SC injection with 
single GAP43-positive fiber visible (arrow); (D) – glaucoma treated with PBS injection, no visible neurites 
outgrowth; (E–F) – glaucoma treated with SC injection, numerous, parallel GAP43-positive fibers detected 
within optic nerve (arrows). Samples were additionally stained for glial marker – GFAP to confirm presence of 
optic nerve reactive gliosis accompanying damage. Scale bar = 20 μm. (G–I) – retinal cross-sections presenting 
different pattern of synaptophysin expression within retina. In healthy retinas (G) synaptophysin expression 
was visible mostly within IPL and OPL, additionally perinuclear staining was visible in INL and punctate in 
GCL. Glaucomatous retinas treated with SC-injection (H) presented increased expression of synaptophysin, 
particularly in IPL. Additionally, strong expression of this synaptic marker was visible in the GCL (arrow). In 
glaucoma samples treated with PBS, decreased expression of synaptophysin within the IPL and outer plexiform 
layer OPL was observed (I). Scale bar = 50 μm. GCL - ganglion cell layer; INL - inner nuclear layer; IPL - inner 
plexiform layer; OPL - outer plexiform layer. SC – Schwann cells; ONC – optic nerve crush.
www.nature.com/scientificreports/
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reports in which the authors demonstrate the absence of these factors52–56. Based on our results, the assumption 
that the observed impact of grafted SC is due to neurotrophic factors remains questionable. Conversely, the lack 
of these factors did not limit the beneficial effect of the use of SC therapy for dying neurons, which suggests that 
the neurotrophic factors are not the only necessary stimulus for SC-dependent neuronal regeneration; it seems to 
be regulated in a more complex way54.
Migration of intravitreally transplanted SC. Impaired migration of transplanted cells within the retinal 
structure is perceived as a basic problem of ocular cell therapies that results in reduced bioavailability of active 
agents secreted by the transplanted cells13,14,57,58. To improve the integration of transplanted cells in vivo, intra-
vitreal injection of proteolytic enzymes, to digest retinal ILM, or suppression of glial cells (i.e., using intravitreal 
α -aminoadipic acid) was reported14. In both cases there was no increase in neuroprotective effect observed14. 
Cell migration in ex vivo conditions can be improved by mechanical breakdown of the ILM continuity through 
Figure 7. Retinal cross-sections, different expression pattern of GAP43 and synaptophysin proteins 
within inner retina. (A) – healthy retina, high synaptophysin expression visible in IPL and single punctate 
staining in GCL (arrow). (B) – glaucomatous retina treated with PBS revealed decreased synaptophysin 
expression within IPL. (C) – glaucomatous retina treated with SC, strong synaptophysin staining visible in IPL, 
additionally intense lineal signal detected in GCL – representation of axonal pattern of synaptophysin (arrows). 
(D) – merged image of staining for synaptophysin and β 3tubulin revealed that lineal expression of synaptophysin 
extends in RGC axons (small arrows) projecting from RGC bodies (big arrows). Scale bar = 20 μm (A–C), 50 μm 
(D). OPL - outer plexiform layer; IPL - inner plexiform layer; GCL - ganglion cell layer; SC - Schwann cells.
www.nature.com/scientificreports/
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pipette tip trauma13,59. Our observations on SC migration and integration with the host retina are opposite to 
those presented by other authors. Based on ex vivo experiment with retinal explants, it might be expected that 
increasing of transplanted cells penetration into the host retina is not beneficial, because it disrupts the layered 
retinal structure, which may cause disintegration of the complex neural network. Additionally, it is important 
to note, the extra-retinal location of transplanted SC in vivo in our study was sufficient to ensure a satisfactory 
neuroprotective and pro-regenerative effect.
Predominance of SC therapy. Different precursor cells indeed exhibited neuroprotective effects, but this 
was accompanied by many problems of a technical nature (e.g., the need for additional intraocular cell activation 
– erythropoietin in the case of Müller cell precursors and inflammatory stimulation in the case of oligodendro-
cytes precursors (zymosan), proteolysis of the retinal ILM, glial cell inhibition with glutamate analogues, immu-
nosuppressive agents due to host versus graft immunoreactivity or uncontrolled proliferation and differentiation 
of transplanted cells) that make putative treatment difficult or even impossible to apply in clinical settings2,11,12,14. 
In our study, the RGC and optic nerve axon survival was similar to that observed in therapy with mesenchymal 
stem cells, and even better than that described for oligodendrocytes precursors and olfactory glial cells10,12,25. 
Therapy with predegenerated SC had an advantage over the cited types of progenitor cells because it did not 
require any additional treatments after transplantation.
Different outcomes of SC transplantation in acute and chronic optic nerve damage. We 
observed differences in the neuroprotective activity of SC between the ONC and glaucoma model; in the second 
one (i.e., glaucoma), SC impact on RGC survival was more pronounced. We suspect that the explanation for this 
phenomenon might be associated with different follow-up times (i.e., 10 days vs 6 weeks). In the glaucoma model, 
longer incubation time in the vitreous potentially allowed transplanted SC to better adapt and was further bene-
ficial to cell functions compared with the short duration in the ONC model. Another reason might be hidden in 
differing mechanisms of neuropathy (i.e., more acute in ONC) and localization of initial damage.
SC transplantation prevents synaptic proteins impairment. Neuroplasticity in glaucoma has 
been described mostly with respect to brain structures; however, changes in retinal synaptic markers expres-
sion were reported with respect to ocular hypertension models60–63. Some authors reported that up to approxi-
mately the 14th day of high-pressure exposure, synaptic proteins were overexpressed in retina, mostly within the 
IPL; then this expression dramatically decreased, which might be indirect evidence of the existence of natural 
pro-regenerative mechanisms that become gradually insufficient during the course of glaucoma62,63. In our study, 
a 6-week duration of ocular hypertension caused visible underexpression of synaptic markers within the retina 
in instances of untreated glaucoma and preservation of synaptic marker overexpression in SC-treated cases. This 
allowed us to conclude that SC therapy might prolong the functioning of natural defensive mechanisms that 
exist in retinal neurons and protect them against depression. Surprisingly, synaptic marker expression was also 
visible within the GCL and RNFL, which might suggests that SC therapy can enhance and extend neuronal web 
regulation, expressed in synaptic proteins synthesis and transport, however this direction would require further 
investigations64.
The novel therapy proposed in this study creates conditions to eliminate some of the identified barriers for 
ocular cells transplantation and allows us to observe direct neuroprotective and pro-regenerative effects in ongo-
ing optic neuropathy without any additional modifications to transplanted cells after intravitreal injection. SC 
represent mature, differentiated cells, which is why almost no risk of uncontrolled proliferation exists. An addi-
tional advantage is that isolating and culturing them is a simple process65. Predegenerated Schwann cells might 
be isolated from each of the peripheral nerves, so they might be prepared and applied also as autotransplants; the 
best quality SC tend to originate from mixed (i.e., sensory-motor) nerves53,54. Based on the above description of 
predegenerated SC therapy, we demonstrated that it might be a promising, effective and easy to apply alternative 
cell therapy for glaucoma.
Methods
Animals. The study protocol was approved by the National Animal Experiment Board (Finland) and the Local 
Ethical Committee of the Medical University of Silesia (Poland). Experiments were conducted in accordance 
with the ARVO statement for the use of Animals in Ophthalmic and Vision Research. In all experiments, we used 
male Wistar rats (Experimental Medicine Center, Medical University of Silesia, Katowice, Poland and Laboratory 
Animal Center, University of Eastern Finland, Kuopio, Finland). For predegenerated Schwann cell culture, we 
included two 8-week-old rats, and for ex vivo experiments, we used four P2 rat pups and eight 4-week-old rats. 
For in vivo experiments we used fifty 40-week-old rats, 30 for the glaucoma model and 20 for the optic nerve 
crush model. Each in vivo group was divided into 2 equal subgroups, one to which we applied cell therapy and 
another to serve as a control group. Experimental in vivo procedures on eyes were performed unilaterally; the 
contralateral eye was kept intact as a healthy control. For animal anesthesia, we used an intraperitoneal injection 
of a mixture of ketamine (50 mg/kg; Ketalar, Pfizer Oy Animal Health, Finland; VetaKetam, VETAGRO, Poland) 
and medetomidine (0.4 mg/kg; Domitor, Orion Oy, Finland) or xylazine (5 mg/kg; Xylapan, Vetoquinol Biowet, 
Poland).
Predegenerated SC culture. Animals for SC isolation were anesthetized; sciatic nerves were cut bilaterally 
at the level of the hip joint, and animals were maintained in standard conditions for 7 days with facilitated access 
to food and water. Thereafter distal stumps of transected sciatic nerves were collected. After collection of nerves, 
animals were sacrificed. The nerves were cultured on 12-well plates at 37 °C in humidified air with 5% CO2 in 
Endothelial Cell Growth Medium (EGM2MV BulleKit, Lonza, Basel, Switzerland) supplemented with 10 μg/ml 
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insulin (Sigma, St. Louis, MO, USA), 12 ng/ml heregulin α (Sigma, St. Louis, MO, USA), 3 µM forskolin (Sigma, 
St. Louis, MO, USA) and 10 μg/ml pituitary bovine extract (Sigma, St. Louis, MO, USA) as described before65. 
The cells, after the third split, were double-stained  with anti-S100 antibody (dilution 1:300) and anti-GFAP 
antibody (dilution 1:1000). The ratio of double immunostained cells was manually calculated from 5 visual fields 
under 40× magnification in relation to DAPI-positive nuclei. After characterization, SC were incubated with 
eGFP-coding lentiviral particles (LV-eGFP, CMV promoter, kindly donated by professor Seppo Ylä-Herttuala, 
Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University 
of Eastern Finland, Kuopio). After the transduction procedure, cells were split, re-cultured twice and collected 
for intravitreal transplantation at a density of 1 × 106 cells in 5 μl of PBS and for ex vivo delivery at a density of 
1 × 104 cells in 2 μl of PBS. For in vivo regeneration and neuroplasticity detection, non-transduced SC were used.
SC proteomics by mass spectrometry. Medium samples and SC homogenate were processed accord-
ing to Grønborg et al. and Varjosalo et al. with the authors’ modifications66,67. Briefly, samples were adjusted 
to a pH 8.0–9.0 with 1.0 M ammonium bicarbonate (Sigma, St. Louis, MO, USA). Tris (2-carboxyethyl) phos-
phine hydrochloride at a final concentration of 5 mM (Sigma, St. Louis, MO, USA) was used for the reduction 
of disulfide bonds at 37 °C for 30 minutes. Iodoacetamide 100 mM (Sigma, St. Louis, MO, USA) was used for 
blocking cysteine residues at RT in the dark for 30 minutes; thereafter, the samples were incubated with trypsin 
(Promega V5113, Madison,WI, USA) with an enzyme to substrate ratio of 1:20 (w/w) at 37 °C overnight. The 
trypsinized samples were purified with C18 silica microspin columns (The Nest Group, Southborough, MA, 
USA) and analyzed on a hybrid LTQ Orbitrap Elite Mass Spectrometer (Thermo Scientific, Rockford, IL, USA) 
coupled to an Easy nLCII (liquid chromatography) nanoflow system (Thermo Scientific, Rockford, IL, USA) via a 
nanoelectrospray ion source (Thermo Scientific, Rockford, IL, USA). The following solvents were used for liquid 
chromatography separation of the digested samples: solvent A (0.1% formic acid, 98% water, 2% acetonitrile), 
and solvent B (0.1% formic acid, 98% acetonitrile, 2% water). Peptides were eluted the analytical column with a 
gradient of 60 min of buffer B ranging from 5% to 35% at a constant flow rate of 300 nl/min followed by a 10 min 
gradient from 35% to 80% of solvent B.
As a positive control for the MS analysis, a solution of 1.0 and 0.1 ng/ml human brain derived neurotrophic 
factor (BDNF, PeproTech EC Ltd, London, UK) and 1.0 and 0.1 ng/ml rat ciliary neurotrophic factor (CNTF, 
PeproTech EC Ltd, London, UK) in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12-  (DMEM-F12, 
Sigma, St. Louis, MO, USA) was used.
Proteomic data analysis. The RAW files were analyzed using Thermo Scientific™ Proteome Discoverer™ 
1.4 software connected to the SEQUEST® search engine, constrained with a precursor mass tolerance of 10 ppm 
and fragment mass tolerance of 0.8 Da, respectively. Spectra were searched against the Protein Knowledgebase 
(UniProtKB reviewed completed Rattus norvegicus database) with the following parameters: enzyme specificity 
was set to Trypsin with up to 2 missed cleavages. Oxidation (+ 15.996 Da) of methionine was selected as a vari-
able modification, carboxymethylated (+ 57.021 Da) cysteine was set as a fixed modification. Data were filtered 
with a peptide confidence set to <5% FDR. Proteins with at least one unique peptide were considered as iden-
tified. Automated annotation of identified proteins was completed with Gene Ontology (GO) classifications by 
Annotation® .
Experimental glaucoma. After rats (n = 30) were anesthetized, ocular hypertension was induced as pre-
viously described, using “the bead model with initial high-pressure injury”, by intracameral injection of 5 μL of 
6-μm-diameter beads (Polybead Microspheres; Polysciences, Inc., Warrington, PA, USA), 5 μL of 10-μm-diameter 
beads and 5 μL of viscoelastic solution (10 mg/mL sodium hyaluronate; Healon; Advanced Medical Optics Inc., 
Santa Ana, CA, USA) using a glass cannula with a 50-μm-diameter tip68. The right eye served as a healthy control. 
IOP measurements were obtained using a laboratory tonometer (TonoLab, Icare, Finland) three times during 
first week and then once a week. The rats were sacrificed 6 weeks after the beads were injected , except of 4 addi-
tional animals sacrificed 2 and 4 weeks after beads injections to evaluate transplanted SC localization. Retinas of 
6 animals from each group were processed as whole mounted for stereology, other were used to prepare paraffin 
cross-sections.
Optic nerve crush. Rats (n = 20) were anesthetized and optic nerve crush (ONC) was performed as 
described previously for mice with modifications according to the species69. The procedure was performed in a 
non-traumatic way, without cutting off the eyelid, which prevented eye surface scarification. The optic nerve was 
exposed via a conjunctival incision and crushed approximately 0.5 mm behind the globe for 10 seconds using a 
self-closing forceps to ensure reproducibility and constant force. The right eye served as a healthy control. The rats 
were euthanized 10 days after ONC. Retinas of 6 animals from each group were processed as whole mounted for 
stereology, other were used to prepare paraffin cross-sections.
Intraocular delivery of Schwann cells. Cell allotransplantation was performed on the day after induction 
of ocular hypertension and the day after the ONC procedure. Injections were administered 1 mm posteriorly to 
the corneal limbus using a 5 μl Hamilton syringe combined with a 34 G needle. After injection, the needle was 
kept in the eye for approximately 2 minutes and area of the insertion wound was covered with antibiotic ointment 
(Oftan Chlora 10 mg/g, Santen Oy, Helsinki, Finland) to reduce the risk of infection and minimize the outflow 
of the cells.
Ex vivo experiments. For the ex vivo study, we used 2 different models of retinal explant preparation and 
culture. To observe the direct impact of predegenerated SC on retinal neurite outgrowths, we prepared reversed 
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:23187 | DOI: 10.1038/srep23187
retinal explants from newborn P2 rats (n = 4). To examine direct interactions between the GCL and SC, a 
co-culture of SC with retinal insert explants from 4 week-old rats (n = 8) was prepared.
Insert retinal explants. Animals for insert explants preparation were sacrificed and their eyeballs were 
collected in an ice cold PBS solution containing 1% penicillin-streptomycin (Gibco, Carlsbad, CA, USA). Retinas 
were isolated from eyeballs, cut into 4 quadrants and placed on culture inserts (0.4 μm Millicell tissue culture 
insert, Millipore, Billerica, MA, USA) with GCL on the top, as previously described13. Inserts were placed in 
a 24-well plate containing culture medium consisting of Neurobasal A (Gibco, Carlsbad, CA, USA) supple-
mented with 5% fetal bovine serum (FBS), 2% B-27 supplement (Gibco, Carlsbad, CA, USA), 1% N2 supple-
ment (Invitrogen, Carlsbad, CA, USA), 1% penicillin-streptomycin solution (Gibco, Carlsbad, CA, USA) and 
0.4% GlutaMax (Gibco, Carlsbad, CA, USA). Thirty-two explants were cultured with 2 µl of SC/PBS suspension 
(approximately 104 cells per explant) placed on each explant surface.  In 16 explants, we avoided contact between 
the pipette tip and the explant surface during placement of the cell suspension drop; another 16 explants received 
a SC suspension accompanied by slight contact of the pipette tip with the explant surface (to mechanically break 
the continuity of the retinal inner limiting membrane – ILM). As a control, we placed 2 μl of PBS on another 16 
explant surfaces without and 16 with pipette tip contact. The medium was changed every second day. After 10 
days of culture at 37 °C and 5% CO2, explants were fixed with 4% PFA overnight at + 4 °C; 10 explants from each 
group were processed as whole mounted retinas for RGC counting using stereology software; cryosections of 6 
explants from each group were processed for immunostainings.
Reversed retinal explants. For reversed explants, rat pups were sacrificed; eyeballs were removed and 
stored in ice cold Neurobasal A medium (Gibco, Carlsbad, CA, USA) containing 1% penicillin-streptomycin 
solution (Gibco, Carlsbad, CA, USA). Retinas were isolated, cut in 4 round parts, and each part was placed on the 
bottom of a 24-well plate with down-orientated GCL, as described by Gaublomme et al.70. Before plating, wells 
were coated overnight at room temperature (RT) with 0.25 mg/ml poly-L-lysine (Sigma, St. Louis, MO, USA) in 
PBS followed by a 2 h-coating with 2 μg/ml laminin (Sigma, St. Louis, MO, USA) in PBS at 37 °C and 5% CO2. 
Explants were cultured in Neurobasal A medium (Gibco, Carlsbad, CA, USA) and supplemented as for insert 
explants; the medium was changed every day. Following this method, we prepared 30 explants: 10 of them were 
cultured in standard medium as a negative control; 10 explants were cultured as a positive control with 5 ng/ml of 
rat BDNF, a known inducer of neurite growth (Life Technologies, Carlsbad, CA, USA); and 10 were co-cultured 
with 103 of predegenerated SC added into each well in parallel with explants plating. After 72 hours, explants were 
fixed with 4% PFA overnight at + 4 °C and processed for immunostaining and neurites tracing.
Optical Coherence Tomography (OCT) imaging. For OCT and fundus photographs, animals with 
transparent optic centers were selected. Scans were obtained from between 4–6 weeks of damage in glaucoma 
group and 3–10 days of damage in ONC group. Because satisfying optical center transparency was difficult to 
achieve after both applied procedures, there was a small number of animals in the subgroups (in the glaucoma 
group 2 animals with SC transplantation and 2 animals with PBS injection, in the ONC model 3 animals with SC 
transplantation and 3 animals with PBS injection). The procedure required general anesthesia and topical mydri-
asis with 0.5% tropicamide (Santen Oy, Helsinki, Finland). OCT scans and fundus photographs were obtained 
with HRT Spectralis OCT (Heidelberg Engineering, Germany). Photographs of the eye fundus as well as retinal 
scans in the parapapillary area were taken with a focus = 32 dptr. We measured the following parameters: optic 
nerve disc, cup, and neuroretinal ring size, cup/disc ratio, retina and retinal nerve fiber layer (RNFL) thickness in 
the central and peripheral retina.
Animal sacrifice. Rats were transcardially perfused under deep anesthesia with 0.9% NaCl for 2 min, fol-
lowed by perfusion with 4% paraformaldehyde/0.1 M PBS, pH 7.4, for 10 min. Eyes were enucleated while pre-
serving retrobulbar optic nerve stumps and post-fixed in 4% paraformaldehyde overnight at + 4 °C; they were 
then washed in PBS overnight and processed for immunohistochemistry.
Immunohistochemistry. Optic nerves were cut off behind the eyeball and divided into 2 stumps. Proximal 
stumps with unmyelinated nerve fibers were processed for immunostainings; distal stumps containing myeli-
nated nerve fibers were used for axon counting. The total number of cells in the GCL was estimated in whole 
mounted retinas; paraffin cross-sections of eyeballs were used for immunostainings. For visualization, we used a 
fluorescent microscope, Zeiss Axio Scope. A1 (Zeiss, Oberkochen, Germany).
Paraffin-embedded retinal sections. After fixation, eyeballs were embedded in paraffin according to a 
standard protocol, sectioned at 5 μm, and prepared for immunostaining by deparaffinization, rehydratation and 
blocking in 10% NGS 0.1% Triton X-100 in 0.05 M TBS for 30 min. Primary antibodies incubation was performed 
overnight at + 4 °C (Supplementary Table 2). After each primary antibody samples were washed in 0.05 M TBS, 
pH 7.4 and incubated for 3 h at room temperature (RT) with an appropriate secondary antibody and washed 
again. To counterstain nuclei, samples were incubated with 1:10 000 dilution of 4′ ,6-diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich, St. Louis, MO, USA) for 10 min at RT and mounted with Mowiol (Calbiochem, CA, USA).
Optic nerves and ex vivo explant cryosections. After overnight fixation in 4% PFA at + 4 °C, optic 
nerves and retinal explants were embedded in an optimal cutting temperature compound (Sakura Finetek Europe 
BV, Netherlands), sectioned at 10 μm, and processed for immunostaining as described earlier.
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Whole mounted retinas and whole mounted ex vivo explants. After fixation, floating samples were 
washed in PBS overnight in + 4 °C and incubated in 20% NGS 0.1% Triton X-100 in 0.05 TBS for 45 min, and 
stained as described earlier.
Retinal reversed ex vivo explants. After fixation, explants were incubated in 20% NGS 0.1% Triton X-100 
in 0.05 TBS for 45 min. Primary antibodies were applied for 3 h at RT followed by a 3 h incubation at RT with a 
secondary antibody. Nuclei were counterstained with 4′ ,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St. 
Louis, MO, USA) for 10 min.
TUNEL assay kit. To visualize apoptotic cells, we performed TUNEL staining on cryosections using a 
30 minute-incubation with 0.1 M Tris-HCl, pH = 7.5/3% BSA/20% NGS followed by a 1 h-incubation with 
an in situ cell death detection kit at 37 °C (Roche, Mannheim, Germany). Nuclei were counterstained with 
4′ ,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO, USA) fluorescent stain (1:10 000 in 0.05 M 
TBS) for 10 minutes and mounted with Mowiol (Calbiochem, CA, USA).
Optic nerve processing for axonal counts. To evaluate optic nerve axon damage, optic nerve 
cross-sections (n = 5 per group) were analyzed using stereological methods. After fixation in 4% paraformal-
dehyde, optic nerves were post-fixed in 1% osmium tetroxide for 30 minutes, dehydrated in a graded ethanol 
series and stained with 1% uranyl acetate in absolute ethanol for 1 hour. After staining, optic nerve stumps were 
infiltrated with epoxy resin at 60 °C for 48 hours, and then, 1 μm thick cross-sections of the optic nerve were cut 
and stained using toluidine blue.
Stereology. The stereological software Stereo Investigator (MicroBrightField Inc, VT, USA) was used to 
count the total number of GCL cells in whole mounted retinas from in vivo experiments, estimate the RGC den-
sity in whole mounted retinal ex vivo insert explants, and count the total number of axons in optic nerve sections. 
To evaluate neurite outgrowth parameters in reversed P2 retinal explants, we performed neurite tracing using 
the stereology software Neurolucida (MicroBrightField Inc, VT, USA). Measurements included the number of 
neurites, their total and mean length [μm], their surface area [μm2], and their arboration rate [%].
Statistics. Statistical analysis was performed with the IBM statistical software SPSS v. 20. Descriptive sta-
tistical results were reported as the mean ± standard deviation (SD). A Kolmogorov–Smirnov test was used 
to check whether the data were normally distributed. Comparisons between groups were performed using a 
Mann-Whitney U-test, paired samples Wilcoxon test or paired samples t-student test. P values < 0.05 were con-
sidered statistically significant.
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